Kategori: Publikationer

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.

Hambardzumyan K, Bolce RJ, Saevarsdottir S, Forslind K, Wallman JK, Cruickshank SE, Sasso EH, Chernoff D, van Vollenhoven RF. RMD Open. 2016 Mar 1;2(1):e000197.

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Cöster L, Forslind K, van Vollenhoven R, Heimbürger M. RMD Open. 2016 Jan 14;2(1):e000133.

MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis.

Forslind K, Svensson B. Scand J Rheumatol. 2016;45(2):99-102.

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P. Arthritis Rheumatol. 2015 Nov;67(11):2855-60.

Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study.

de Rooy DP, Tsonaka R, Andersson ML, Forslind K, Zhernakova A, Frank-Bertoncelj M, de Kovel CG, Koeleman BP, van der Heijde DM, Huizinga TW, Toes RE, Houwing-Duistermaat JJ, Ospelt C, Svensson B, van der Helm-van Mil AH. J Rheumatol. 2015 Aug;42(8):1383-91.

Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.

Levitsky A, Forslind K, van Vollenhoven RF; SWEFOT trial group. Scand J Rheumatol. 2015;44(5):348-53.